MedTrace Logo

Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin

NCT02963922 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2020-03-30

Study results available
· View outcomes & findings →

Summary

This trial is conducted globally. The aim of this trial is to investigate effect and safety of liraglutide 3.0 mg in subjects with overweight or obesity and type 2 diabetes mellitus treated with basal insulin.

Conditions

  • Metabolism and Nutrition Disorder
  • Obesity

Interventions

DRUG

Liraglutide 3.0 mg

Injected subcutaneously (s.c., under the skin) once daily

DRUG

Placebo

Injected subcutaneously (s.c., under the skin) once daily

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-02-06
Primary Completion
2018-09-10
Completion
2018-09-25
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Germany
  • Israel
  • Italy
  • Mexico
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02963922 on ClinicalTrials.gov